Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CM 355

Next Previous
Drug Profile

CM 355

Alternative Names: CM355; ICP-B02; PRO-203

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoCare Pharma; KeyMed Biosciences
  • Developer InnoCare Pharma; KeyMed Biosciences; Prolium Bioscience
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma; Systemic scleroderma
  • Clinical Phase Unknown Systemic lupus erythematosus

Most Recent Events

  • 03 Mar 2026 Prolium plans a clinical trial for B-cell driven autoimmune disorders in 2026
  • 03 Mar 2026 Prolium Bioscience plans a phase I/II trial for Systemic scleroderma in the second quarter of 2026
  • 03 Mar 2026 Updated efficacy data from a phase I/II trial in B-cell lymphoma released by Prolium Bioscience

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top